Cargando…

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date

Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults worldwide. The advent of intravitreal neutralization of vascular endothelial growth factor (VEGF) has revolutionized the management of patients with neovascular AMD, but current anti-VEGF therapies carry...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Eric R, Kaiser, Peter K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245454/ https://www.ncbi.nlm.nih.gov/pubmed/32546942 http://dx.doi.org/10.2147/OPTH.S194234

Ejemplares similares

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

Ranibizumab port delivery system: a clinical perspective
por: Eichenbaum, David A, et al.
Publicado: (2022)

Improving treatment provision of Wet AMD with intravitreal ranibizumab
por: Ghazala, Fadi, et al.
Publicado: (2013)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab for the treatment of wet AMD: a summary of real-world studies
por: Chong, V
Publicado: (2016)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery
por: Ranade, Shrirang V., et al.
Publicado: (2022)

Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists
por: Sharma, Ashish, et al.
Publicado: (2023)

Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji, Tsuyoshi, et al.
Publicado: (2013)

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
por: Hatamnejad, Amin, et al.
Publicado: (2023)

Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2022)

The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab
por: Dikmetas, Ozlem, et al.
Publicado: (2013)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
por: Providência, Joana, et al.
Publicado: (2018)

Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis
por: Tsai, Ching-Yao, et al.
Publicado: (2023)

EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL
por: Bantseev, Vladimir, et al.
Publicado: (2020)

Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study
por: Asahi, Masumi G, et al.
Publicado: (2020)

The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

Unravelling the therapeutic potential of IL-33 for atrophic AMD
por: Clare, Alison J., et al.
Publicado: (2021)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date
por: Kim, Jean, et al.
Publicado: (2020)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

Erratum to: The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD)
por: Nashine, Sonali
Publicado: (2021)

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
por: Matsumiya, Wataru, et al.
Publicado: (2013)

Gene expression levels of the insulin-like growth factor family in patients with AMD before and after ranibizumab intravitreal injections
por: Strzalka-Mrozik, Barbara, et al.
Publicado: (2017)

Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
por: Chang, Margaret A., et al.
Publicado: (2022)

Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme
por: Holz, Frank G, et al.
Publicado: (2013)

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
por: Butt, Thomas, et al.
Publicado: (2015)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date
por: Soogrim, Vicki, et al.
Publicado: (2021)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
por: Lenert, Aleksander, et al.
Publicado: (2017)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021)

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date
por: Dorey-Stein, Zachariah L, et al.
Publicado: (2021)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ac1ls7q71m3frjnfro10tnm40p